Literature DB >> 21819449

Clinical and prognostic reports from 270 patients with multiple primary melanomas: a 34-year single-institution study.

P Savoia1, S Osella-Abate, T Deboli, F Marenco, E Stroppiana, M Novelli, M T Fierro, M G Bernengo.   

Abstract

BACKGROUND: Development of more than one primary melanoma in a sole patient is frequent, accounting for 1.2-8.2% of melanoma patients in most recent series. OBJECTIVE AND METHODS: Clinical, histological and epidemiological characteristics of 270 multiple primary melanomas patients were reviewed.
RESULTS: Two-hundred and seven patients (76.7%) had two melanomas, whereas in the remaining 63 the number of primary ranged from three to eight; on the whole, 639 multiple primary melanomas were identified. Synchronous melanomas developed more frequently in patients with three or more lesions; median age was significantly lower in the group of patients with more than three melanomas than in the others. Mean Breslow's thickness significantly decreases (P<0.001) from the first (1.77±1.76 mm) to subsequent primaries (0.85±1.25 mm for the second and 0.66±0.48 mm for the third melanoma). Percentage of 'in situ' melanomas was 5.6% as first diagnosis, but increased to 24.8% for the second melanoma; number of nodular melanomas was significantly lower for succeeding diagnosis. AJCC stage at diagnosis showed a statistical prognostic significance, whereas outcome and survival did not depend on the number of primary lesions. Multivariate analysis confirmed the prognostic role of Breslow's thickness, ulceration, gender and patient age, and the better prognosis of patients with multiple melanomas, respect to those with single primary melanoma.
CONCLUSIONS: Skin examination and long-term follow-up are mandatory for patients affected by melanoma, with the intent to promptly diagnose not only a disease progression but also possible new primary melanomas.
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2011        PMID: 21819449     DOI: 10.1111/j.1468-3083.2011.04181.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

1.  Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis.

Authors:  Emi Dika; Elisabetta Broseghini; Elisa Porcellini; Martina Lambertini; Mattia Riefolo; Giorgio Durante; Phillipe Loher; Roberta Roncarati; Cristian Bassi; Cosimo Misciali; Massimo Negrini; Isidore Rigoutsos; Eric Londin; Annalisa Patrizi; Manuela Ferracin
Journal:  Cell Death Dis       Date:  2021-05-12       Impact factor: 8.469

2.  Survival between synchronous and non-synchronous multiple primary cutaneous melanomas-a SEER database analysis.

Authors:  Jie Xiong; Yanlin Su; Zhitong Bing; Bihai Zhao
Journal:  PeerJ       Date:  2020-01-03       Impact factor: 2.984

3.  Eleven Primary Melanomas, Colon Cancer, and Atypical Nevi in the Same Patient: A Case Report and Literature Review.

Authors:  Lea Juul Nielsen; Lisbet Rosenkrantz Hölmich
Journal:  Case Rep Dermatol Med       Date:  2016-02-28

4.  Cutaneous melanoma frequencies and seasonal trend in 20 years of observation of a population characterised by excessive sun exposure.

Authors:  Serena Bonin; Antonio Albano; Nicola di Meo; Alessandro Gatti; Giuseppe Stinco; Fabrizio Zanconati; Giusto Trevisan
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

5.  Association of a novel point mutation in MSH2 gene with familial multiple primary cancers.

Authors:  Hai Hu; Hong Li; Feng Jiao; Ting Han; Meng Zhuo; Jiujie Cui; Yixue Li; Liwei Wang
Journal:  J Hematol Oncol       Date:  2017-10-03       Impact factor: 17.388

6.  Epidemiological and histopathological aspects of primary cutaneous melanoma in residents of Joinville, 2003-2014.

Authors:  Raquel Bissacotti Steglich; Karina Munhoz de Paula Alves Coelho; Silvana Cardoso; Maria Helena da Costa Naumann Gaertner; Tania Ferreira Cestari; Selma Cristina Franco
Journal:  An Bras Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.